Department of Otolaryngology, Head - Neck Surgery and Audiology, Aalborg University Hospital, Denmark;Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Unit of Clinical Biostatistics and Bioinformatics, Aalborg University Hospital, Aalborg, Denmark.
J Int Adv Otol. 2020 Aug;16(2):176-182. doi: 10.5152/iao.2020.6320.
The primary objective of this study was to evaluate how successful the reposition of retractable benign paroxysmal positional vertigo (BPPV) was when treating patients with the Thomas Richard Vitton (TRV) reposition chair.
This is a prospective clinical trial. A total of 81 BPPV patients who were referred to the tertiary Balance - Dizziness Centre at the Department of Otolaryngology, Head - Neck Surgery and Audiology, Aalborg University Hospital, Denmark were included and analyzed. All the patients were diagnosed and treated with the TRV reposition chair.
The patients were successfully treated after an average of 2.23 (± 1.66 SD) treatments with the TRV reposition chair. There was a significant difference between the number of treatments needed in the single semicircular canal group and the multicanal group. Seventeen (22.6%) of the patients experienced either dislocation of otoconia, relapse, or new onset of BPPV during the trial period. The number of patients with BPPV located to the anterior, lateral, and multiple semicircular canals in this study was significantly higher than that in similar studies. Six patients (7.4%) were classified as treatment failures.
We found the TRV reposition chair to be very successful in the diagnostics and treatment of patients with retractable and atypical BPPV. However, 7.4% experienced treatment failure.
本研究的主要目的是评估可复位良性阵发性位置性眩晕(BPPV)患者采用托马斯·理查德·维顿(TRV)复位椅治疗的复位成功率。
这是一项前瞻性临床试验。共纳入并分析了 81 例转诊至丹麦奥尔堡大学医院耳鼻喉科-头颈外科和听力学平衡-头晕中心的 BPPV 患者。所有患者均采用 TRV 复位椅进行诊断和治疗。
患者平均接受 2.23(±1.66SD)次 TRV 复位椅治疗后成功复位。单半规管组和多管组之间所需治疗次数存在显著差异。17 例(22.6%)患者在试验期间出现耳石脱位、复发或新发 BPPV。本研究中前、外和多半规管 BPPV 患者的数量明显高于类似研究。6 例(7.4%)患者被归类为治疗失败。
我们发现 TRV 复位椅在诊断和治疗可复位和非典型 BPPV 患者方面非常成功。然而,7.4%的患者治疗失败。